Significant advancements in oncology treatments and clinical research findings highlight today's medical news landscape.
Key Points
The ASTRO has updated its guidance to strengthen recommendations for the use of radiation therapy in treating pancreatic cancer.
The FDA approved the RAS inhibitor daraxonrasib for metastatic pancreatic cancer, which has shown success in doubling patient survival rates compared to standard chemotherapy.
A new zanidatamab-based regimen for HER2-positive gastroesophageal adenocarcinoma has been approved by the FDA, yielding an overall survival rate of 26.4 months.
A comprehensive meta-analysis indicates that cannabis use is associated with an earlier onset of psychosis by an average of 2.5 years.
Clinical research suggests that the drug vutrisiran may play a critical role in stabilizing right ventricular function in patients suffering from transthyretin amyloidosis with cardiomyopathy.
The drug brepocitinib has demonstrated efficacy in providing rapid and sustained improvements for skin disease and itch in adult patients with dermatomyositis.
New diagnostic criteria for preclinical vascular cognitive impairment have linked the condition to increased cardiovascular risk and higher mortality rates in adults without dementia.
Long-term venom immunotherapy has been deemed safe for children with Hymenoptera venom allergies, with studies reporting no severe systemic reactions during treatment.